Marktanalyse - Medulloblastoma - Pipeline Review, H2 2016

Global Markets Direct
12.2016
95 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Medulloblastoma - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Medulloblastoma — Pipeline Review, H2 2016, provides an overview of the Medulloblastoma (Oncology) pipeline landscape.

Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occur in the cerebellum, which is the part of brain located at the base of the skull, just above the brainstem. Symptoms associated with a medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Medulloblastoma — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Medulloblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Medulloblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 3 and 12 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Medulloblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Medulloblastoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Medulloblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Medulloblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Medulloblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Medulloblastoma (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Medulloblastoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Medulloblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Medulloblastoma Overview 8

Therapeutics Development 9

Pipeline Products for Medulloblastoma - Overview 9

Pipeline Products for Medulloblastoma - Comparative Analysis 10

Medulloblastoma - Therapeutics under Development by Companies 11

Medulloblastoma - Therapeutics under Investigation by Universities/Institutes 12

Medulloblastoma - Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Medulloblastoma - Products under Development by Companies 15

Medulloblastoma - Products under Investigation by Universities/Institutes 16

Medulloblastoma - Companies Involved in Therapeutics Development 17

Bayer AG 17

DelMar Pharmaceuticals Inc 18

Ignyta Inc 19

IMPACT Therapeutics Inc 20

Lipocure Ltd 21

MacroGenics Inc 22

NewLink Genetics Corp 23

Novogen Ltd 24

Progenics Pharmaceuticals Inc 25

Stemline Therapeutics Inc 26

ThromboGenics NV 27

VBI Vaccines Inc 28

Vyriad Inc 29

Medulloblastoma - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Combination Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

(topotecan hydrochloride + vincristine sulfate) - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

dianhydrogalactitol - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Edotreotide Labeled Yttrium 90 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

IMP-5471 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

indoximod - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

irinotecan hydrochloride + TBio-02 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

nifurtimox - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

nifurtimox SR - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Oncolytic Virus to Target CD46 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

p28 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

pyrvinium pamoate - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

SL-301 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

taladegib - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

THR-317 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Trilexium - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

VBI-1901 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Vimo-101 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

VMY-1103 - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Medulloblastoma - Dormant Projects 86

Medulloblastoma - Product Development Milestones 87

Featured News & Press Releases 87

Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting 87

Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations 87

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe 88

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit 89

Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program 89

Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083 90

Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant 91

Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors 91

Appendix 94

Methodology 94

Coverage 94

Secondary Research 94

Primary Research 94

Expert Panel Validation 94

Contact Us 94

Disclaimer 95





List of Tables

Number of Products under Development for Medulloblastoma, H2 2016 9

Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Medulloblastoma - Pipeline by Bayer AG, H2 2016 17

Medulloblastoma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016 18

Medulloblastoma - Pipeline by Ignyta Inc, H2 2016 19

Medulloblastoma - Pipeline by IMPACT Therapeutics Inc, H2 2016 20

Medulloblastoma - Pipeline by Lipocure Ltd, H2 2016 21

Medulloblastoma - Pipeline by MacroGenics Inc, H2 2016 22

Medulloblastoma - Pipeline by NewLink Genetics Corp, H2 2016 23

Medulloblastoma - Pipeline by Novogen Ltd, H2 2016 24

Medulloblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2016 25

Medulloblastoma - Pipeline by Stemline Therapeutics Inc, H2 2016 26

Medulloblastoma - Pipeline by ThromboGenics NV, H2 2016 27

Medulloblastoma - Pipeline by VBI Vaccines Inc, H2 2016 28

Medulloblastoma - Pipeline by Vyriad Inc, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Assessment by Combination Products, H2 2016 31

Number of Products by Stage and Target, H2 2016 33

Number of Products by Stage and Mechanism of Action, H2 2016 35

Number of Products by Stage and Route of Administration, H2 2016 37

Number of Products by Stage and Molecule Type, H2 2016 39

Medulloblastoma - Dormant Projects, H2 2016 86





List of Figures

Number of Products under Development for Medulloblastoma, H2 2016 9

Number of Products under Development for Medulloblastoma - Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 32

Number of Products by Stage and Top 10 Targets, H2 2016 32

Number of Products by Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 34

Number of Products by Routes of Administration, H2 2016 36

Number of Products by Stage and Routes of Administration, H2 2016 36

Number of Products by Molecule Types, H2 2016 38

Number of Products by Stage and Molecule Types, H2 2016 38

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus